OncoGenex sinks, sees prostate potential after custirsen failure

OncoGenex Pharmaceuticals shares fell 60.3% after the company and its partner Teva Pharmaceutical Industries revealed that custirsen did not significantly improve survival versus chemotherapy for prostate cancer patients enrolled in the Phase III SYNERGY clinical trial.

OncoGenex Pharmaceuticals shares fell 60.3% after the company and its partner Teva Pharmaceutical Industries revealed that custirsen did not significantly improve survival versus chemotherapy for prostate cancer patients enrolled in the Phase III SYNERGY clinical trial.

Bothell, Washington-based OncoGenex closed at $3.85 per share on 28 April versus $9.70 before the weekend. The company shed $86.1m...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

More from Therapy Areas